NumFin

Paratek Pharmaceuticals, Inc.

Sümbol: PRTK

NASDAQ

2.23

USD

Turuhind täna

  • -3.0521

    P/E suhe

  • 0.1791

    PEG suhe

  • 127.83M

    MRK Cap

  • 0.00%

    DIV tootlus

Paratek Pharmaceuticals, Inc. (PRTK) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete Paratek Pharmaceuticals, Inc. (PRTK) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 22.574 M, mis on 22.363 % gowth. Kogu perioodi keskmine brutokasum on 19.805 M, mis on 22.423 %. Keskmine brutokasumi suhtarv on 0.849 %. Ettevõtte eelmise aasta tulemuse puhaskasv on 0.076 %, mis on võrdne -0.435 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes Paratek Pharmaceuticals, Inc. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus -0.062. Käibevara valdkonnas on PRTK aruandlusvaluutas 136.842. Märkimisväärne osa neist varadest, täpsemalt 34.248, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust -0.641%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 0, kui neid on, aruandlusvaluutas. See näitab erinevust 0.000% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 258.414 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on 0.010%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud -171.042 aruandlusvaluutas. Selle aspekti aastane muutus on 0.338%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 78.038, varude hind on 16.57 ja firmaväärtus 0.83, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 0. Kontovõlad ja lühiajalised võlad on vastavalt 5.31 ja 0. Koguvõlg on 258.41, netovõlg on 224.17. Muud lühiajalised kohustused moodustavad 32.08, mis lisandub kohustuste kogusummale 343.58. Lõpuks hinnatakse viidatud aktsia 0, kui see on olemas.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014201320122011201020092008200720062005200420022001

balance-sheet.row.cash-and-short-term-investments

178.9734.295.5125.2
215.4
292.8
151.7
128
131.3
95.9
70
85.3
62.4
68
88.9
85.1
94.6
64.6
50.5
46.6
0
0

balance-sheet.row.short-term-investments

29.92015.120
113.1
203.4
116.3
75.1
0
0
60.1
45.9
51.7
54.3
71.9
70.2
69.9
50.1
14.5
38.4
0
0

balance-sheet.row.net-receivables

190.457833.115.7
9.6
0.2
5.9
0.3
0.7
4.4
2.9
0.3
0
0
0
0.5
11.5
0.2
0.2
0.5
0
0

balance-sheet.row.inventory

62.7216.61114.6
11.6
-42.2
0.2
0.8
2.4
0
-2.9
8.3
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

41.917.912.47.8
6.5
4.4
2.7
2.9
7.9
1
3.6
1.1
3.5
1.5
1.5
0.5
1.6
0.9
0
0
0
0

balance-sheet.row.total-current-assets

474.42136.8152.1164.1
243.4
255.2
160.5
132.1
142.4
101.3
73.6
95
65.8
69.4
90.4
86
107.8
65.7
51.7
47.6
0
0

balance-sheet.row.property-plant-equipment-net

8.632.42.63
3.7
1.2
1.7
1.2
0.8
0
0
0.1
0.3
0.6
1.1
0
1.1
0.1
0.3
0.2
0
0

balance-sheet.row.goodwill

3.320.80.80.8
0.8
0.8
0.8
0.8
0.8
0.8
0
3
3
3
3
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0.1
1
1.3
4.8
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

3.320.80.80.8
0.8
0.8
1
1.8
2.2
5.6
0
3
3
3
3
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

0000
0
42.5
0
0
0
0
0
0
0
0
0
0
40.4
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

140.1132.528.48.9
3.2
0.5
0.5
0.6
0.5
2.9
0
0
0
0.8
0.8
0.8
-39.4
0.2
0.3
0.2
0
0

balance-sheet.row.total-non-current-assets

152.0635.731.812.7
7.7
44.9
3.2
3.6
3.5
8.6
0
3.1
3.3
4.4
4.8
0.8
2
0.4
0.5
0.4
0
0

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

626.48172.5183.9176.9
251.1
300.2
163.7
135.7
145.9
110
73.7
98.1
69.2
73.8
95.2
86.8
109.8
66.1
52.3
48
41.9
3.9

balance-sheet.row.account-payables

21.685.35.41.8
4.1
2.1
3.6
4.4
0.8
0.5
0.4
1
1
0.6
0.7
1.1
4.2
2.4
2.6
1.4
0
0

balance-sheet.row.short-term-debt

164.04000
0
0
0
0
0
0
0
0
0
1.4
0.5
0
5
0
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

872.3258.4255.7252
262.8
229
59.2
39
19.6
0
0
0
0
0
0.6
0
0
0
0
0
0
0

Deferred Revenue Non Current

0000
0
0
0
0
0
0
0
0
0
0
7.4
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

91.232.125.922.1
20.1
15.6
13.2
16
19.7
3.3
1.5
1.7
2.4
0.4
2.4
1.6
0
3.8
2.1
1.3
0
0

balance-sheet.row.total-non-current-liabilities

1042.35306.2280.4255.2
266.5
234.9
64.4
43.7
24.2
11
0
0
0.1
0.3
8.1
0.1
44.9
0
108
82.9
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

4.891.51.31.5
2.1
0
0
0
0
0
0
0
0
0
0.9
0
0
0
0
0
0
0

balance-sheet.row.total-liab

1354.08343.6311.7279.1
290.7
252.6
81.2
64.1
44.7
14.7
1.9
2.7
3.4
10
24.1
2.8
64.1
6.2
112.7
85.6
0
0

balance-sheet.row.preferred-stock

0000
0
0
0
135.7
145.9
110
0
0
0
0
95.2
0
25.1
66.1
0
0
0
0

balance-sheet.row.common-stock

0.230.10.1705.5
671.5
630.2
552.7
0
370
0
211.3
207.5
165.8
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

-3769.48-930.4-866.9-807.8
-711.3
-582.5
-470.1
-380.4
-268.7
-197.9
-139.6
-112.1
-100.1
-96.2
-86.9
-89.1
-123.9
-91.4
-61.7
-37.9
-7.2
-1.6

balance-sheet.row.accumulated-other-comprehensive-income-loss

-0.12000
0.1
-0.1
-0.2
0
-515.9
-110
0
0
0
0
0
0.4
-0.1
-1.3
-2.2
-0.1
0
0

balance-sheet.row.other-total-stockholders-equity

3041.77759.4739.10
-0.1
0.1
0.2
316.2
-145.9
183.1
0
0
0
160
62.7
172.7
144.6
86.4
3.5
0.5
0.2
0.1

balance-sheet.row.total-stockholders-equity

-727.6-171-127.8-102.3
-39.7
47.7
82.6
71.6
101.2
95.2
71.7
95.4
65.8
63.8
71.1
84
45.7
59.8
-60.4
-37.6
-7
-1.5

balance-sheet.row.total-liabilities-and-stockholders-equity

626.48172.5183.9176.8
251
300.3
163.9
135.7
145.9
110
73.7
98.1
69.2
73.8
95.2
86.8
109.8
66.1
52.3
48
41.9
3.9

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

-727.6-171-127.8-102.3
-39.7
47.7
82.6
71.6
101.2
95.2
71.7
95.4
65.8
63.8
71.1
84
45.7
59.8
-60.4
-37.6
-7
-1.5

balance-sheet.row.total-liabilities-and-total-equity

626.48---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

29.92015.120
113.1
245.9
116.3
75.1
0
0
60.1
45.9
51.7
54.3
71.9
70.2
69.9
50.1
14.5
38.4
0
0

balance-sheet.row.total-debt

1036.34258.4255.7252
262.8
229
59.2
39
19.6
0
0
0
0
0
1.1
0
0
0
0
0
0
0

balance-sheet.row.net-debt

887.3224.2175.4146.9
160.5
-63.9
-92.5
-14
-111.7
-95.9
-9.9
-39.4
-10.7
-13.7
-15.9
-14.9
-24.7
-14.4
-36
-8.2
0
0

Rahavoogude aruanne

Paratek Pharmaceuticals, Inc. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab -0.360 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 7.33, mis tähistab 7.692 erinevust võrreldes eelmise aastaga. Huvitav on see, et osa ettevõtte aktsiatest, täpsemalt 0, ostis ettevõte ise tagasi. Selle tegevuse tulemusena muutus 0.000 võrreldes eelmise aastaga. Vahepeal on ettevõtte võlgnevused praegu 7.68 aruandlusvaluutas. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli 14804000.000. See on 2.282 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 0.49, 0, -2.89, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte 0 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui 0.65, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004

cash-flows.row.net-income

-62.73-63.6-59.1-96.5
-128.8
-112.4
-89.1
-111.6
-70.9
-17.8
-27.4
-12
0
-9.3
-21.8
34.8
-32.5
-29.6
-23.8
-18

cash-flows.row.depreciation-and-amortization

0.310.50.40.6
-1.3
-1.1
1.3
2.3
0.7
0.2
0.1
0.2
0.4
0.5
0.6
1.1
0.5
0.7
0.5
0.1

cash-flows.row.deferred-income-tax

0001.1
0
0.1
0.7
0
2.9
9.1
0
0
0
0
1.2
0.1
0
0
0
0

cash-flows.row.stock-based-compensation

10.3412.314.310.2
14.3
25.5
16.9
10.8
5.1
0.7
3.3
2.9
4.4
1.9
1.4
2.8
0
0
0
0

cash-flows.row.change-in-working-capital

23.96-20.8-8.2-20.3
-21.5
3.9
-8.2
4.5
10.5
-11.5
5.4
-6.7
-7.5
-13.6
19.7
-48.6
45.5
1.8
1.7
0.8

cash-flows.row.account-receivables

-5.71-40.4-21.8-7.5
-11.2
4.4
-4.8
5
-2.7
-4.8
0
0
0
0
0
11.5
0
0
0
0

cash-flows.row.inventory

-2.05-9.1-15.5-11.8
-10.9
-0.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

8.967.76.81.6
-0.6
-0.6
0
0
0
0
-0.6
0
0.4
-0.1
0.2
0
0
0
0
0

cash-flows.row.other-working-capital

22.762122.3-2.6
1.2
0.8
-3.4
-0.4
13.2
-6.7
6
-6.7
-7.9
-13.5
19.5
-60.1
45.5
1.8
1.7
0.8

cash-flows.row.other-non-cash-items

4.915.44.31.5
3.2
2.7
0.6
-0.1
-0.1
9.9
3.8
0.4
-2.9
1
1
-1.1
4.3
1.2
0.1
0

cash-flows.row.net-cash-provided-by-operating-activities

-23.22000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-0.070-0.4-0.4
-0.2
-0.1
-1.1
-0.7
-0.9
0
0
0
-0.1
-0.1
-0.3
0
-1.1
0
-0.2
-0.1

cash-flows.row.acquisitions-net

0000
-0.2
-0.7
0
0
0
13.7
0
0
0
0
48
0
0
0
0
0

cash-flows.row.purchases-of-investments

-15.16-15.2-15.1-29.6
-102.2
-292.9
-180.3
-135.8
0
0
-69.8
-41
-52.2
-106.6
-128.3
-135.6
-128.4
-97.2
-16.3
-51.1

cash-flows.row.sales-maturities-of-investments

303020122.5
237
165.1
138.7
60.1
0
0
54.7
46.3
53.5
122.8
95.3
136.6
108.8
61.5
40.4
52.3

cash-flows.row.other-investing-activites

15.2000
0.2
0.7
0.7
1.6
0.3
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

29.9714.84.592.5
134.6
-127.9
-42
-74.8
-0.6
13.7
-15.1
5.2
1.3
16.1
14.7
1
-20.6
-35.6
23.9
1

cash-flows.row.debt-repayment

-3.73-2.9-0.3-70
0
0
0
0
0
0
0
0
0
0
-3.4
0
0
0
0
0

cash-flows.row.common-stock-issued

07.318.421.9
26.6
51.5
82.8
70.9
71.3
89.8
0.4
38.7
1.4
0.2
0.5
0.1
13.2
39.9
25.4
0.1

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

-0.120.70.359.4
31.1
169.2
20.2
19.6
19.5
9.7
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-cash-used-provided-by-financing-activities

-3.575.118.311.3
57.6
220.7
103
90.5
90.7
99.5
0.4
38.7
1.4
0.2
-2.9
0.1
13.2
39.9
25.4
0.1

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

3.18-46.2-25.40.4
58.1
11.7
-17.5
-78.3
35.4
94.6
-29.4
28.7
-3.1
-3.3
12.6
-9.8
10.3
-21.6
27.8
-15.9

cash-flows.row.cash-at-end-of-period

149.5534.480.6106
105.6
47.5
35.4
53
131.3
95.9
9.9
39.4
10.7
13.7
17
14.9
24.7
14.4
36
8.2

cash-flows.row.cash-at-beginning-of-period

146.3780.6106105.6
47.5
35.8
53
131.3
95.9
1.2
39.4
10.7
13.7
17
4.4
24.7
14.4
36
8.2
24.1

cash-flows.row.operating-cash-flow

-23.22-66.1-48.3-103.4
-134
-81.2
-78.6
-94.1
-54.7
-18.5
-14.8
-15.2
-5.7
-19.5
0.8
-10.9
17.7
-25.9
-21.5
-17.1

cash-flows.row.capital-expenditure

-0.070-0.4-0.4
-0.2
-0.1
-1.1
-0.7
-0.9
0
0
0
-0.1
-0.1
-0.3
0
-1.1
0
-0.2
-0.1

cash-flows.row.free-cash-flow

-23.29-66.2-48.6-103.8
-134.3
-81.2
-79.7
-94.8
-55.5
-18.5
-14.8
-15.2
-5.8
-19.6
0.5
-10.9
16.6
-25.9
-21.6
-17.2

Kasumiaruande rida

Paratek Pharmaceuticals, Inc. tulud muutusid võrreldes eelmise perioodiga 0.247%. PRTK brutokasum on teatatud 127.73. Ettevõtte tegevuskulud on 173.94, mille muutus võrreldes eelmise aastaga on 23.761%. Kulud amortisatsioonikulud on 0.49, mis on 1.942% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 173.94, mis näitab 23.761% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab -0.123% kasvu võrreldes eelmise aastaga. Tegevustulu on -46.21, mis näitab 0.123% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on 0.076%. Eelmise aasta puhaskasum oli -63.57.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004200320022001

income-statement-row.row.total-revenue

167.74150.812143.5
16.5
17.1
12.6
0
0
4.3
1.7
11
19.7
12.5
5.2
60.6
16.7
0.4
0.1
1.1
1.3
0.4
0

income-statement-row.row.cost-of-revenue

25.323.121.58.7
3.5
0
0
0
0
0
0
0
0
2
2.2
0
0
0
0
0
0
0
0

income-statement-row.row.gross-profit

142.45127.799.434.9
13.1
17.1
12.6
0
0
4.3
1.7
11
19.7
10.5
3
60.6
16.7
0.4
0.1
1.1
1.3
0.4
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

38.83---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-7.38-9.5-9.2-3.4
0
0
0
0
0
-0.3
3
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.operating-expenses

186.99173.9140.5110.4
128.7
121.2
97
109.9
70.8
10.9
26.2
22.9
23.5
21.7
25.1
28.6
53.3
33.1
24.9
19.9
0
6.2
1.6

income-statement-row.row.cost-and-expenses

212.29197162.1119
132.2
121.2
97
109.9
70.8
10.9
26.2
22.9
23.5
21.7
25.1
28.6
53.3
33.1
24.9
19.9
0
6.2
1.6

income-statement-row.row.interest-income

0.990.80.11.5
3.6
3.3
1.4
1.1
0
0
0
0
0.1
0.1
0.3
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

18.8618.117.420.2
16.4
11
5.1
3.2
0.8
0.7
-0.1
-0.2
0
0
0.2
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-12.98-17.3-17.4-21
-12.9
-0.1
-0.2
0.3
0.7
-10.6
-3
-0.2
-0.2
-0.2
-2.1
2.8
4.1
3.1
0
0
0
0
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-7.38-9.5-9.2-3.4
0
0
0
0
0
-0.3
3
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.total-operating-expenses

-12.98-17.3-17.4-21
-12.9
-0.1
-0.2
0.3
0.7
-10.6
-3
-0.2
-0.2
-0.2
-2.1
2.8
4.1
3.1
0
0
0
0
0

income-statement-row.row.interest-expense

18.8618.117.420.2
16.4
11
5.1
3.2
0.8
0.7
-0.1
-0.2
0
0
0.2
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

0.951.30.41.6
3.5
-1.1
1.3
2.3
0.7
0.2
0.1
0.2
0.4
0.5
0.6
1.1
0.5
0.7
0.5
0.1
0
0
0

income-statement-row.row.ebitda-caps

-43.4---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-44.54-46.2-41.1-75.5
-115.6
-104.1
-84.6
-109.5
-70.1
-7.8
-27.4
-11.9
-3.8
-9.2
-22.1
32
-36.7
-32.7
-24.9
-18.8
1.3
-5.9
-1.6

income-statement-row.row.income-before-tax

-62.56-63.5-58.5-96.5
-128.5
-111.9
-88.3
-111.6
-70.9
-17.8
-27.4
-12
-4
-9.4
-24.1
34.8
-32.5
-29.6
0
0
0
0
0

income-statement-row.row.income-tax-expense

4.560.10.619.7
0.3
0.5
0.8
3.2
0
0.4
2.9
-0.2
-0.4
0.1
1.4
-2.8
-4.1
-3.1
-1.1
-0.8
12.8
5.6
1.6

income-statement-row.row.net-income

-67.12-63.6-59.1-116.3
-128.8
-112.4
-89.1
-111.6
-70.9
-17.8
-27.4
-12
-3.9
-9.3
-21.8
34.8
-32.5
-29.6
-23.8
-18
-12.8
-5.6
-1.6
Sarnased aktsiad
Sind võib huvitada ka:
SRNE
Sorrento Therapeutics, Inc..
0.015 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
8.97 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.03 USD
NASDAQ
GUBRA.CO
Gubra A/S.
300 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.1 NOK
OSL
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.35 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

Korduma kippuv küsimus

Mis on Paratek Pharmaceuticals, Inc. (PRTK) koguvara?

Paratek Pharmaceuticals, Inc. (PRTK) koguvara on 172538000.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on 67270000.000.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.850.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on -0.190.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on -0.299.

Mis on ettevõtte kogutulu?

Kogutulu on -0.201.

Mis on Paratek Pharmaceuticals, Inc. (PRTK) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on -63566000.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 258414000.000.

Mis on tegevuskulude arv?

Tegevuskulud on 173941000.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 42685000.000.